Vasopharm

company

About

Vasopharm is focused on the R&D of novel therapeutics for the treatment of cerebro and cardiovascular diseases and their symptoms.

  • 1 - 10

Details

Last Funding Type
Private Equity(PE)
Last Funding Money Raised
€9.50M
Industries
Biotechnology,Medical,Therapeutics
Founded date
Jul 1, 1998
Number Of Employee
1 - 10
Operating Status
Active

vasopharm is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. In this area, the company is focused on the development of therapeutics influencing the bioavailability of nitric oxide (NO), a cellular signalling molecule involved in many physiological and pathological processes. vasopharm’s drug candidate VAS203 is an allosteric NO synthase inhibitor and represents a completely new class of modulators of nitric oxide synthase (NOS) enzymes. It rapidly lowers excessive NO production in cerebral vessels and tissues, thereby preventing life-threatening increases in intracranial pressure and associated inflammatory processes following traumatic brain injury.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
€29.50M $18.30M
Vasopharm has raised a total of €29.50M $18.30M in funding over 2 rounds. Their latest funding was raised on Jul 11, 2019 from a Private Equity(PE) round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 11, 2019 Private Equity(PE) €9.50M 3 EF Investments — Detail
Jan 21, 2016 Series G €20M 1 — — Detail
Jun 24, 2013 Series F $6.50M 1 — — Detail
Jan 30, 2006 Series B $11.80M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Vasopharm is funded by 3 investors. EF Investments and Future Capital Development Fund are the most recent investors.
Investor Name Lead Investor Funding Round
EF Investments Yes Private Equity(PE)
Future Capital Development Fund — Private Equity(PE)
Bayern Kapital — Private Equity(PE)